NCT05883137 High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
| NCT ID | NCT05883137 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Stockholm |
| Condition | Critical Illness |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-09-25 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2023-09-25 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Intubation in the intensive care unit is a standard procedure with a high risk of adverse events such as hypoxaemia and cardiovascular instability. However, it is demonstrated that HFNO (High Flow Nasal Oxygen) for pre and perioxygenation is feasible and, in many situations, prolongs the safe apnoeic period after anaesthesia induction. Previous data of the use of HFNO during intubation of the critically ill is conflicting. With the new device Optiflow Switch, which allow its combination with NIV or tight facemask with perioxygenation, we aim to evaluate whether this could reduce intubation-related hypoxaemia and other adverse events. The general purpose of this project is to compare the addition of Optiflow Switch for pre- and perioxygenation to traditional preoxygenation using a tight-fitting mask or NIV during intubation in adult intensive care patients in a prospective before-and-after study design.
Eligibility Criteria
Inclusion Criteria: * Adult, ≥18 years old * Intensive care patients that require tracheal intubation for any indication Exclusion Criteria: * Patients with skull or facial injuries where the application of nasal cannula is to be avoided, decided by the intensivist. * Pregnancy * Total nasal obstruction * Deemed not suitable for any other reason than the aforementioned
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05883137 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Critical Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05883137 currently recruiting?
Yes, NCT05883137 is actively recruiting participants. Contact the research team at ida-maria.forsberg@regionstockholm.se for enrollment information.
Where is the NCT05883137 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT05883137 clinical trial?
NCT05883137 is sponsored by Region Stockholm. The trial plans to enroll 150 participants.